RxDoctor Payments Data

Thomas Messe, MD

Family Medicine · Pace, FLNPI 1366422784

Payments from drug & device makers

$726in general payments, 2019–2025

Across 43 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$135
  • Pfizer$133
  • Amgen$106
  • GSK$78
  • Dexcom, Inc.$67
  • AbbVie$52
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$726 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$144,263
Medicare patients
359
Services billed
2,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab61$230,662
EliquisApixaban164$188,024
OzempicSemaglutide141$172,954
TrulicityDulaglutide91$136,363
JanuviaSitagliptin Phosphate70$92,168
JardianceEmpagliflozin73$78,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$60,005
MounjaroTirzepatide28$47,595
XareltoRivaroxaban36$43,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog176$38,227
FarxigaDapagliflozin Propanediol29$29,003
LinzessLinaclotide19$23,919
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$21,493
Breo ElliptaFluticasone/Vilanterol34$19,024
Lidocaine52$17,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$23$190,341133 claims
PfizerEliquis$133$188,024164 claims
Novo NordiskOzempic$135$172,954141 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$78$94,552151 claims
MerckJanuvia$12$92,16870 claims
AstraZenecaFarxiga, Symbicort$12$41,41366 claims
AbbVieLinzess$52$23,91919 claims
Astellas Pharma US IncMyrbetriq$47$16,11716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →